CompletedNCT01495169
Iloperidone Safety and Drug Levels in Adolescents
About this title
Read the official source — NCT01495169Medication studyAges 12–17United StatesBipolarity
Understand this study
Who was this study for?
Listed age limits: 12 years to 17 years.
- Listed locations
- Costa Mesa and 9 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateOctober 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 33
- Sponsor
- Vanda Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 12 Years to 17 Years
- Official registry ID
- NCT01495169
- Official title
Show the full official title
A Multicenter, Open-label, Sequential Cohort, Dose-escalation, 14-day Study to Explore the Tolerability and Pharmacokinetics of Iloperidone 12 to 24 mg/Day Followed by 26 Weeks of Flexible Dosing (6 to 24 mg/Day) in Adolescent Patients (Aged 12 to 17 Years)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Costa Mesa · North Miami · Atlanta
7 more locations
- Coeur d'Alene
- Baltimore
- St Louis
- Marlton
- Cincinnati
- Cleveland
- Salt Lake City
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Vanda Pharmaceuticals.
Did this study involve medication?
Yes. The study involved medication, including iloperidone (oral tablet).
Who was this study for?
Listed age limits: 12 years to 17 years.
